Research and Markets has announced the addition of the "Traveler's Diarrhea - Pipeline Review, H2 2016" report to their offering.
Traveler's Diarrhea pipeline therapeutics constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities Institutes.
Traveler's Diarrhea - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Traveler's Diarrhea Traveler's diarrhea is a stomach and intestinal infection that occurs as a result of unsanitary handling of food. Symptoms include abdominal cramps, nausea, vomiting and fever. Predisposing factors include age, weakened immune systems, diabetes or inflammatory bowel disease and acid blockers or antacids.
Treatment includes anti-motility agents and antibiotics. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/qcvkxp/travelers
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005984/en/Business Wire
Last updated on: 13/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.